Protein Isoform Determination

Protein isoforms

Posttranslational modification (PTM), like glycosylation, results in a huge number of protein variants (isoforms) showing micro heterogeneity of different kinds. The dominating heterogeneity is found in the carbohydrate moieties of glycoproteins. Other examples are genetic polymorphism, modified functional groups in amino acids by e.g. phosphorylation, acetylation, or limited proteolysis. No protein seems to be homogenous and many proteins show a huge number of different isoforms. The distribution of the isoforms might change due to physiological regulation and pathological processes and the distribution pattern seems to have high clinical significance. Production of a typical pattern from one cell-type may affect the whole isoform distribution in the circulation. The glycosylation of proteins seems to be an important regulator for the fine-tuning of biological activity. Isoforms show various interactions with receptors which also can affect their survival time. In cancer, inflammation or liver diseases, the protein glycosylation pattern is typically changed at an early stage of the disease. The need for protein isoform detection ranges from high abundance proteins like haemoglobin (10^-3 M) down to proteins like erythropoietin (10^-15 M).

Protein isoform determination

The distribution of isoforms seems to have high impact on the biological function as well as being an indicator of pathological conditions, but the lack of suitable methods hampers the clinical use of isoform diagnostics.
Few quantitative methods are available for determination of isoforms, especially for measurement of low concentrations in biological specimens. A combination of discrete steps of separation (electrophoresis or chromatography) and detection (immunological technique) is used. The quality of the test depends on the type of specific isoforms that can be distinguished, how efficiently these isoforms are separated (resolution), and how well they can be quantified (specificity and sensitivity). The electrophoretic or chromatographic separations in columns are gentle techniques which do not require extensive pre-preparation of the biological sample. The advantage with chromatographic separation is the possibility to use different ligands for isoform separation. Analysis of the fractions using immunoassay is quantitative, sensitive and specific, although quite expensive. Slab-gel and capillary electrophoresis separate isoforms due to charge differences but lack suitable means to quantify and specify correctly. Mass spectrometry detection does not solve these specificity and quantification problems, especially not when analysing low abundance glycoproteins. An affinity based pre-treatment step that specifically captures the protein of interest and concentrates it in relation to other proteins will enhance the possibilities to use these types of methods. None of the available techniques is suitable for high-throughput testing or for point-of-care applications. The chromatographic approach, utilizing selected ligands for separation, in combination with immunoassay seems to be the best way for quantitative isoform detection but a miniaturisation is needed.

Urgent need for better methods for isoform analysis

Several interesting and valuable analytes appear in low concentrations and show extensive micro-heterogeneity which causes variable results when using available test kits. Prostate specific antigen (PSA), about 100 pM in serum, appears mainly in complexes with other proteins. It shows degradation products and differences in the carbohydrate chains and should be a better marker for prostate cancer if the relevant isoform pattern, including glycoforms, could be determined. Cardiac troponin I (cTnI), about 3 pM in serum, is released into the circulation after myocardial injury (MI). It appears in complexes with other proteins, and may undergo both oxidation and phosphorylation as well as proteolysis after release. cTnI is a marker with wide diagnostic window, but abnormal levels appear late after the onset of MI. The isolated measurement of early released non-degraded isoforms will most probably result in earlier diagnosis. Erythropoietin (EPO), about 0.3 pM in urine, is a glycoprotein hormone with about 40% carbohydrate and probably several hundreds of isoforms appearing in normal samples, and as such, a challenging analyte. Methods for identification of aberrant EPO isoform profiles have been developed for identification of illegal use of recombinant EPO, which enhances the performance during sport competitions. Profiles of differently charged EPO isoforms can be shown by column electrophoresis combined with sensitive immunoassay quantification of the fractions. The presently accredited EPO doping test is using isoelectric focusing and a double immunoblotting technique. These tests take several days to perform and are very expensive.

Development of new methods

MAIIA (Membrane Assisted Isoform ImmunoAssay) is a novel lab-on-a-chip based technology for rapid and sensitive measurement of protein isoforms in biological specimens. The chromatographic zone can be provided with suitable ligands, such as lectins and receptors, as well as charged ones, and the porous monolith shows excellent chromatographic properties. The technology has been utilized to show the transferrin isoform profile, to measure carbohydrate-deficient transferrin as well as to distinguish low amounts of recombinant and endogenous EPO present in urine. The MAIIA technology seems to fulfil the requirements as a rapid and sensitive isoform determination method with potential to resolve and detect several types of PTM isoforms even when they appear in the femto-molar (10^-15 M) concentration range.